AbbVie revenue jumps 17.8 pct on higher demand for drug Humira
July 29 (Reuters) - AbbVie Inc's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.
The company, which acquired cancer drug developer Stemcentrx, said net revenue rose to $6.45 billion in the second quarter ended June 30 from $5.48 billion, a year earlier.
Net profit increased to $1.61 billion, or 98 cents per share, from $1.37 billion, or 83 cents per share.
(Reporting by Natalie Grover in Bengaluru; Editing by Kirti Pandey)
Terms and Privacy Policy